Selected article for: "action mechanism and low nanomolar"

Author: Mazalovska, Milena; Kouokam, J. Calvin
Title: Lectins as Promising Therapeutics for the Prevention and Treatment of HIV and Other Potential Coinfections
  • Document date: 2018_5_8
  • ID: 0spmy8vn_12
    Snippet: Cyanovirin-N (CV-N) is a lectin that was firstly isolated from the cyanobacterium Nostoc ellipsosporum, in an attempt to discover anti-HIV agents from natural extracts [19] . The CV-N lectin consists of 101 amino acids with a molecular weight of 11 kDa and contains two carbohydrate-binding sites with specificity towards the terminal 1,2-mannose sugars on high-mannose glycans [34] . CV-N has broad neutralization activity in the low nanomolar range.....
    Document: Cyanovirin-N (CV-N) is a lectin that was firstly isolated from the cyanobacterium Nostoc ellipsosporum, in an attempt to discover anti-HIV agents from natural extracts [19] . The CV-N lectin consists of 101 amino acids with a molecular weight of 11 kDa and contains two carbohydrate-binding sites with specificity towards the terminal 1,2-mannose sugars on high-mannose glycans [34] . CV-N has broad neutralization activity in the low nanomolar range against primary isolates and laboratory-adapted strains of HIV-1 and HIV-2, simian immunodeficiency virus (SIV), and feline immunodeficiency virus [35] . This broad activity of CV-N is due to high affinity of binding to gp120, essential for its anti-HIV effects. The mechanism of action of CV-N is still not quite understood, but it is believed that the antiviral activity against HIV occurs after virus-cell attachment or at a post-CD4-binding step in the entry process [36] . Unfortunately, CV-N treatment results in cell activation, mitogenicity, and increased cytokine production in human PMBC [37] .

    Search related documents:
    Co phrase search for related documents
    • amino acid and broad activity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • amino acid and carbohydrate bind: 1, 2, 3
    • amino acid and cell activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • amino acid and cytokine production: 1, 2, 3, 4, 5, 6, 7, 8
    • amino acid and entry process: 1, 2, 3, 4, 5, 6
    • amino acid and feline immunodeficiency: 1, 2
    • amino acid and feline immunodeficiency virus: 1, 2
    • amino acid and high affinity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • amino acid and high mannose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • amino acid and high mannose glycan: 1, 2
    • anti hiv agent and broad activity: 1
    • antiviral activity and cell activation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • antiviral activity and cytokine production: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • antiviral activity and entry process: 1, 2, 3, 4, 5, 6, 7
    • antiviral activity and feline immunodeficiency: 1, 2, 3, 4
    • antiviral activity and feline immunodeficiency virus: 1, 2, 3, 4
    • antiviral activity and high affinity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • antiviral activity and high mannose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
    • antiviral activity and high mannose glycan: 1, 2, 3